Metabolic manipulation in chronic heart failure: Study protocol for a randomised controlled trial

Roger M. Beadle; Lynne K. Williams; Khaild Abozguia; Kiran Patel; Francisco Leyva Leon; Zaheer Yousef; Anton Wagenmakers; Michael P. Frenneaux

doi:10.1186/1745-6215-12-140

Metabolic manipulation in chronic heart failure: Study protocol for a randomised controlled trial

Roger M. Beadle, Lynne K. Williams, Khaild Abozguia, Kiran Patel, Francisco Leyva Leon, Zaheer Yousef, Anton Wagenmakers, Michael P. Frenneaux

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Heart failure is a major cause of morbidity and mortality in society. Current medical therapy centres on neurohormonal modulation with angiotensin converting enzyme inhibitors and β-blockers. There is growing evidence for the use of metabolic manipulating agents as adjunctive therapy in patients with heart failure. We aim to determine the effect of perhexiline on cardiac energetics and alterations in substrate utilisation in patients with non-ischaemic dilated cardiomyopathy.

Original language	English
Article number	140
Journal	Trials
Volume	12
DOIs	https://doi.org/10.1186/1745-6215-12-140
Publication status	Published - 6 Jun 2011

Keywords

Adenosine Triphosphate
Cardiac Catheterization
Cardiomyopathy, Dilated
Cardiovascular Agents
Double-Blind Method
Drug Monitoring
Echocardiography, Doppler
Energy Metabolism
Great Britain
Heart Failure
Humans
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Myocardium
Perhexiline
Phosphocreatine
Placebo Effect
Prospective Studies
Recovery of Function
Research Design
Stroke Volume
Time Factors
Treatment Outcome
Ventricular Function, Left

Access to Document

10.1186/1745-6215-12-140Licence: CC BY

Cite this

@article{adfe7de5af454b33808bbf214083717a,

title = "Metabolic manipulation in chronic heart failure: Study protocol for a randomised controlled trial",

abstract = "Heart failure is a major cause of morbidity and mortality in society. Current medical therapy centres on neurohormonal modulation with angiotensin converting enzyme inhibitors and β-blockers. There is growing evidence for the use of metabolic manipulating agents as adjunctive therapy in patients with heart failure. We aim to determine the effect of perhexiline on cardiac energetics and alterations in substrate utilisation in patients with non-ischaemic dilated cardiomyopathy.",

keywords = "Adenosine Triphosphate, Cardiac Catheterization, Cardiomyopathy, Dilated, Cardiovascular Agents, Double-Blind Method, Drug Monitoring, Echocardiography, Doppler, Energy Metabolism, Great Britain, Heart Failure, Humans, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Myocardium, Perhexiline, Phosphocreatine, Placebo Effect, Prospective Studies, Recovery of Function, Research Design, Stroke Volume, Time Factors, Treatment Outcome, Ventricular Function, Left",

author = "Beadle, {Roger M.} and Williams, {Lynne K.} and Khaild Abozguia and Kiran Patel and Leon, {Francisco Leyva} and Zaheer Yousef and Anton Wagenmakers and Frenneaux, {Michael P.}",

note = "Acknowledgements: This is an investigator-led study kindly funded by the British Heart Foundation (PG/06/105).",

year = "2011",

month = jun,

day = "6",

doi = "10.1186/1745-6215-12-140",

language = "English",

volume = "12",

journal = "Trials",

issn = "1745-6215",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Metabolic manipulation in chronic heart failure: Study protocol for a randomised controlled trial

AU - Beadle, Roger M.

AU - Williams, Lynne K.

AU - Abozguia, Khaild

AU - Patel, Kiran

AU - Leon, Francisco Leyva

AU - Yousef, Zaheer

AU - Wagenmakers, Anton

AU - Frenneaux, Michael P.

N1 - Acknowledgements: This is an investigator-led study kindly funded by the British Heart Foundation (PG/06/105).

PY - 2011/6/6

Y1 - 2011/6/6

N2 - Heart failure is a major cause of morbidity and mortality in society. Current medical therapy centres on neurohormonal modulation with angiotensin converting enzyme inhibitors and β-blockers. There is growing evidence for the use of metabolic manipulating agents as adjunctive therapy in patients with heart failure. We aim to determine the effect of perhexiline on cardiac energetics and alterations in substrate utilisation in patients with non-ischaemic dilated cardiomyopathy.

AB - Heart failure is a major cause of morbidity and mortality in society. Current medical therapy centres on neurohormonal modulation with angiotensin converting enzyme inhibitors and β-blockers. There is growing evidence for the use of metabolic manipulating agents as adjunctive therapy in patients with heart failure. We aim to determine the effect of perhexiline on cardiac energetics and alterations in substrate utilisation in patients with non-ischaemic dilated cardiomyopathy.

KW - Adenosine Triphosphate

KW - Cardiac Catheterization

KW - Cardiomyopathy, Dilated

KW - Cardiovascular Agents

KW - Double-Blind Method

KW - Drug Monitoring

KW - Echocardiography, Doppler

KW - Energy Metabolism

KW - Great Britain

KW - Heart Failure

KW - Humans

KW - Magnetic Resonance Imaging

KW - Magnetic Resonance Spectroscopy

KW - Myocardium

KW - Perhexiline

KW - Phosphocreatine

KW - Placebo Effect

KW - Prospective Studies

KW - Recovery of Function

KW - Research Design

KW - Stroke Volume

KW - Time Factors

KW - Treatment Outcome

KW - Ventricular Function, Left

U2 - 10.1186/1745-6215-12-140

DO - 10.1186/1745-6215-12-140

M3 - Article

C2 - 21645332

VL - 12

JO - Trials

JF - Trials

SN - 1745-6215

M1 - 140

ER -